Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Jérôme Courcambeck"'
Autor:
Eloïne Bestion, Zuzana Macek Jilkova, Jean-Louis Mège, Marie Novello, Keerthi Kurma, Seyedeh Tayebeh Ahmad Pour, Gilles Lalmanach, Lise Vanderlynden, Lionel Fizanne, Firas Bassissi, Madani Rachid, Jennifer Tracz, Jérôme Boursier, Jérôme Courcambeck, Cindy Serdjebi, Christelle Ansaldi, Thomas Decaens, Philippe Halfon, Sonia Brun
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 11 (2020)
Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GN
Externí odkaz:
https://doaj.org/article/1f2c4f5fc156452bb5c3b4df23efc116
Autor:
Jonathan Stauber, Maximilian G. Plach, Ahmed Hamaï, Jean-Pierre Baudoin, Philippe Halfon, Marie Novello, Madani Rachid, Eloïne Bestion, Zuzana Macek Jilkova, Soraya Mezouar, Lise Vanderlynden, Gilles Lalmanach, Gaël S. Roth, Raphael Legouffe, Jennifer Tracz, Thomas Schubert, Firas Bassissi, Thomas Decaens, Sonia Brun, Christelle Ansaldi, Cindy Serdjebi, Eric Raymond, Cyrille Drouot, Jérôme Courcambeck, Guillaume Jacquemot
Publikováno v:
Autophagy
Autophagy, 2022, 18 (3), pp.678-694. ⟨10.1080/15548627.2021.1988357⟩
Autophagy, Taylor & Francis, 2022, 18 (3), pp.678-694. ⟨10.1080/15548627.2021.1988357⟩
Autophagy, 2022, 18 (3), pp.678-694. ⟨10.1080/15548627.2021.1988357⟩
Autophagy, Taylor & Francis, 2022, 18 (3), pp.678-694. ⟨10.1080/15548627.2021.1988357⟩
International audience; Hepatocellular carcinoma is the most frequent primary liver cancer. Macroautophagy/autophagy inhibitors have been extensively studied in cancer but, to date, none has reached efficacy in clinical trials. In this study, we demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963947ad8357c65d781ce7a48a965de8
https://hal.science/hal-03677289
https://hal.science/hal-03677289
Autor:
Sonia, Brun, Eloïne, Bestion, Eric, Raymond, Firas, Bassissi, Zuzana Macek, Jilkova, Soraya, Mezouar, Madani, Rachid, Marie, Novello, Jennifer, Tracz, Ahmed, Hamaï, Gilles, Lalmanach, Lise, Vanderlynden, Raphael, Legouffe, Jonathan, Stauber, Thomas, Schubert, Maximilian G, Plach, Jérôme, Courcambeck, Cyrille, Drouot, Guillaume, Jacquemot, Cindy, Serdjebi, Gael, Roth, Jean-Pierre, Baudoin, Christelle, Ansaldi, Thomas, Decaens, Philippe, Halfon
Publikováno v:
Autophagy. 18(3)
Hepatocellular carcinoma is the most frequent primary liver cancer. Macroautophagy/autophagy inhibitors have been extensively studied in cancer but, to date, none has reached efficacy in clinical trials. In this study, we demonstrated that GNS561, a
Autor:
Soraya Mezouar, Elena Patricia Gifu, Philippe Halfon, Julie Pannequin, Firas Bassissi, Thomas Decaens, Sonia Brun, Philippe Merle, Claude Caron de Fromentel, Zuzana Macek-Jilkova, Eloïne Bestion, Jean-Marc Pascussi, Jérôme Courcambeck, Guanxiong Wang
Publikováno v:
American Journal of Cancer
American Journal of Cancer, Adis, 2021, 12 (18), pp.5432-5438. ⟨10.7150/jca.58533⟩
American Journal of Cancer, 2021, 12 (18), pp.5432-5438. ⟨10.7150/jca.58533⟩
Journal of Cancer
American Journal of Cancer, Adis, 2021, 12 (18), pp.5432-5438. ⟨10.7150/jca.58533⟩
American Journal of Cancer, 2021, 12 (18), pp.5432-5438. ⟨10.7150/jca.58533⟩
Journal of Cancer
Patients with advanced hepatocellular carcinoma (HCC) or metastatic colorectal cancer (mCRC) have a very poor prognosis due to the lack of efficient treatments. As observed in several other tumors, the effectiveness of treatments is mainly hampered b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e00ac566bb93f79bbd4a29cc51ec557
https://hal.archives-ouvertes.fr/hal-03326462
https://hal.archives-ouvertes.fr/hal-03326462
Autor:
Eric Raymond, Marie Guillemot, Sonia Brun, Philipe Halfon, Jennifer Tracz, Firas Bassissi, François Autelitano, Cindy Serdjebi, Christelle Ansaldi, Marie Novello, Philippe Fabre, Jérôme Courcambeck
Publikováno v:
Investigational New Drugs
Investigational New Drugs, 2019, 37 (6), pp.1135-1145. ⟨10.1007/s10637-019-00741-3⟩
Investigational New Drugs, Springer Verlag, 2019, 37 (6), pp.1135-1145. ⟨10.1007/s10637-019-00741-3⟩
Investigational New Drugs, 2019, 37 (6), pp.1135-1145. ⟨10.1007/s10637-019-00741-3⟩
Investigational New Drugs, Springer Verlag, 2019, 37 (6), pp.1135-1145. ⟨10.1007/s10637-019-00741-3⟩
International audience; Among the acquired modifications in cancer cells, changes in lysosomal phenotype and functions are well described, making lysosomes a potential target for novel therapies. Some weak base lipophilic drugs have a particular affi
Autor:
Philippe Halfon, Christelle Ansaldi, Seyedeh Tayebeh Ahmad Pour, Jennifer Tracz, Eloïne Bestion, Keerthi Kurma, Zuzana Macek Jilkova, Jérôme Boursier, Lionel Fizanne, Cindy Serdjebi, Lise Vanderlynden, Firas Bassissi, Thomas Decaens, Sonia Brun, Madani Rachid, Marie Novello, Gilles Lalmanach, Jérôme Courcambeck, Jean-Louis Mege
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 11 (2020)
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease, 2020, 11, pp.204062232094204. ⟨10.1177/2040622320942042⟩
Therapeutic Advances in Chronic Disease
Therapeutic Advances in Chronic Disease, 2020, 11, pp.204062232094204. ⟨10.1177/2040622320942042⟩
Background: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GN
Autor:
Ugo Pradere, Jérôme Courcambeck, Raymond F. Schinazi, Tony Whitaker, Chengwei Li, Franck Amblard, Peng Liu, Lavanya Bondada, Ramu Rondla, Tamara R. McBrayer, Steven J. Coats, Philippe Halfon, Drew R. Bobeck, Philip Tharnish
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:6325-6330
Herein, we report the synthesis and structure–activity relationship studies of new analogs of boceprevir 1 and telaprevir 2. Introduction of azetidine and spiroazetidines as a P2 substituent that replaced the pyrrolidine moiety of 1 and 2 led to th
Autor:
Nolwenn Amrani, Philippe Halfon, Jean-Marc Sabatier, Jérôme Courcambeck, Régis Perbost, Besma Jouirou, G. Pèpe, Mourad Bouzidi, Patrice Cacoub
Publikováno v:
Antiviral Therapy. 11:847-856
Background/aims One of the main issues in the development of antiviral therapy is the emergence of drug-resistant viruses. In the case of hepatitis C virus (HCV), selection of drug-resistant mutants was evidenced by in vitro studies on protease inhib
Publikováno v:
Tetrahedron. 61:3725-3731
Diastereomers of tert-butyl-N-Boc-3-ethyl-4-hydroxy- l -prolinate 1 and 2 have been synthesized in six steps starting from readily available Boc-protected trans-4-hydroxy- l -proline. The key reactions in the synthesis are asymmetric reductions, firs
Autor:
Joëlle Boretto, Bruno Canard, Jérôme Courcambeck, Boulbaba Selmi, Joséphine Sire, Jerome Deval, Philippe Halfon, Sarah Garrido-Urbani, Jean-Marc Navarro
Publikováno v:
Journal of Biological Chemistry. 279:25489-25496
Mechanisms governing viral replicative capacity are poorly understood at the biochemical level. Human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) K65R or L74V substitutions confer viral resistance to 2',3'-dideoxyinosine (ddI) in